Monashee Investment Management LLC Has $4.38 Million Stock Position in Compass Therapeutics, Inc. $CMPX

Monashee Investment Management LLC lifted its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 657.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,250,000 shares of the company’s stock after purchasing an additional 1,085,000 shares during the period. Compass Therapeutics accounts for approximately 2.2% of Monashee Investment Management LLC’s holdings, making the stock its 17th largest holding. Monashee Investment Management LLC’s holdings in Compass Therapeutics were worth $4,375,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Creative Planning acquired a new position in Compass Therapeutics in the second quarter valued at about $30,000. Strs Ohio acquired a new position in shares of Compass Therapeutics during the 1st quarter worth about $34,000. Apollon Wealth Management LLC bought a new stake in shares of Compass Therapeutics in the 3rd quarter valued at about $35,000. Welch & Forbes LLC bought a new stake in shares of Compass Therapeutics in the 3rd quarter valued at about $52,000. Finally, Profund Advisors LLC acquired a new stake in shares of Compass Therapeutics in the 3rd quarter valued at approximately $58,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CMPX has been the subject of a number of analyst reports. Craig Hallum initiated coverage on shares of Compass Therapeutics in a report on Friday, February 13th. They set a “buy” rating and a $15.00 price objective for the company. Cantor Fitzgerald began coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They set an “overweight” rating on the stock. Wall Street Zen raised shares of Compass Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 16th. D. Boral Capital restated a “buy” rating and issued a $30.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, January 6th. Finally, Citizens Jmp set a $10.00 price objective on Compass Therapeutics in a research note on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $13.36.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $5.65 on Friday. The firm has a market cap of $1.00 billion, a P/E ratio of -12.56 and a beta of 1.46. Compass Therapeutics, Inc. has a twelve month low of $1.33 and a twelve month high of $6.88. The firm’s 50 day moving average price is $5.86 and its two-hundred day moving average price is $4.72.

Compass Therapeutics Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.